Sage Journals: Discover world-class research

Abstract

D-PLEX100 (D-PLEX) is a novel product candidate made of a polymer-lipid-based matrix (PLEX platform) which contains doxycycline that is being released at a constant rate for 30 days. D-PLEX was developed to prevent surgical site infections, which are a major global health challenge. Previous studies have shown its safety in adult humans, adult swine, and adult rabbits. The aim of this study was to assess the toxicity and safety of D-PLEX also in juvenile animals to support future clinical trials in pediatric patients. Yucatan miniature swine were selected as a model, primarily due to their relatively larger mass. D-PLEX or placebo (formulation without doxycycline) was administered locally to abdominal incisions, and the animal's safety parameters were followed for 9 months and compared to sham-control swine. There was no evidence of any systemic safety concern or local toxicity at the incision site in D-PLEX-treated animals. D-PLEX was detected after 1 month and was fully resorbed at the 3-month time point. The surgical incision sites were fully healed at the 6-month time point in all D-PLEX-treated animals. Toxicokinetic (TK) assessments revealed that doxycycline exhibited low C_max and therefore minimal systemic exposure following a single dose of local administration. This study provides evidence for the safety of D-PLEX and PLEX-based formulation in juvenile miniature swine and supports its further testing in clinical pediatric population. In addition, it can be used as a reference for future preclinical studies aiming to evaluate the safety of other PLEX-based product candidates for the pediatric population.

Keywords

safety biodegradation toxicity swine preclinical surgical site infection juvenile

Introduction

Surgical site infections (SSIs) are a major cause for mortality, increasing the risk by 11-fold, and represent a significant burden on the healthcare system, costing an estimated US$3.3 billion annually in the USA alone.^1,2 SSIs can on average extend hospital stays by 9.7 days, resulting in an average of US$25,000 additional cost per case,^1,3–5 and can delay postoperative treatment and worsen patient outcome.⁶ To avoid the unwanted event of SSI, systemic antibiotic prophylaxis is often used. However, this method has limitations in its effectiveness since the local concentration of the given antibiotic at the surgical site may not reach the necessary levels, resulting in ineffective prophylaxis.^7–9 The medical conditions known to be associated with lower local concentrations include peripheral vascular disease, obesity, and diabetes.^9–12

To overcome this hurdle, various techniques for delivering antibiotics directly to the surgical site have been developed. Such a local drug delivery system is D-PLEX (PolyPid Ltd, Petah Tikva, Israel), which pairs an innovative Polymer-Lipid Encapsulation matriX (PLEX) technology platform with the broad-spectrum antibiotic, doxycycline. The PLEX matrix forms a protected drug reservoir and enables localized and continuous release of doxycycline for a period of 30 days. By that, D-PLEX can provide controlled antibacterial activity directly at the surgical site, while keeping systemic antibiotic exposure very low.^9,13

The safety of D-PLEX in adult animals has been demonstrated previously in preclinical in vivo studies in a sternal surgical defect model in New Zealand white rabbits and in an abdominal surgical incision model in miniature swine. Full absorption of D-PLEX was observed after 9 and 6 months in both models, respectively.^7,8 D-PLEX was also tested in adult patients, undergoing cardiac and colorectal surgeries, and was found to be safe in both types of surgery, and also effective in reducing superficial and deep SSIs in the colorectal surgery cohort.^9,13 Nevertheless, the safety of D-PLEX in the pediatric population is still unknown. This information is particularly relevant because SSIs pose significant challenges in pediatric surgeries. Due to limited data, there is still uncertainty about the most effective prophylactic protocols.^14,15 Even less is known about the use of local antibiotic prophylactic using biodegradable materials in preclinical models to evaluate their potential impact on pediatric development. It is for this reason that we performed this comprehensive study to assess the safety of D-PLEX in juvenile Yucatan miniature swine during 9 months of follow-up. The aim is to provide the groundwork for future clinical trials involving pediatric patients

Materials and Methods

Treatment Protocol

The study was conducted in Altasciences Preclinical Columbia, LLC, Missouri, USA, in compliance with the Food and Drug Administration (FDA) Good Laboratory Practice (GLP) regulations for Nonclinical Laboratory Studies (Title 21 of the Code of Federal Regulations, Part 58), as accepted by Regulatory Authorities throughout the European Union (OECD), Principles of Good Laboratory Practice, Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement. D-PLEX placebo (without Doxycycline) and D-PLEX were provided by PolyPid Ltd, Petah Tikva, Israel. D-PLEX is composed of β-tricalcium phosphate particles (50-100 μm) coated with a controlled release polymer-lipid-based matrix incorporating doxycycline hyclate.^7,8

A total of 96 juvenile Yucatan miniature swine were treated in this study, including 48 males (28 to 35 days of age with a body weight of 3.2 to 6.3 kg prior to dosing initiation) and 48 females (28 to 35 days of age with a body weight of 2.9 to 6 kg prior to dosing initiation). The animals were randomly divided into 4 treatment groups (24 animals per group, 12/sex/group): Sham (surgery only), Placebo (D-PLEX with no Doxycycline), D-PLEX low dose (.77 mg/kg of Doxycycline), and D-PLEX high dose (3.1 mg/kg of Doxycycline) (Table 1).

Table 1.

D-PLEX and Doxycycline Doses.

Group	D-PLEX or Placebo Applied		Doxycycline Free Base Applied^a		Doxycycline Free Base Dose (mg/kg)
Group	mg/Kg^b	mg/Cm^c	mg/Kg^b	mg/Cm^c	Doxycycline Free Base Dose (mg/kg)
Group 1 (two incisions, Sham surgery only)	N/A	N/A	N/A	N/A	N/A
Group 2 (two incisions, Placebo^d only)	∼284	∼142	0	0	0
Group 3 (one incision, D-PLEX treated)	∼71	∼71	.77	.77	.77
Group 4 (two incisions, D-PLEX treated)	∼284	∼142	3.1	1.5	3.1

N/A = Not applicable.

^aDoxycycline free base = 1.09% of D-PLEX (w/w).

^bStudy animal body weight ∼5 kg.

^cIncision length = ∼5 cm.

^dPlacebo = D-PLEX formulation without Doxycycline (excipients only).

Surgical Procedures

One ∼5 cm lateral skin incision was made in the left side of the abdomen of the animals treated with low dose of D-PLEX (Group 3). Two lateral skin incisions (∼5 cm per incision) per animal were made in animals in the Sham, Placebo, and D-PLEX high dose groups (Groups 1, 2, and 4): one in the left side of the abdomen and one in the right side of the abdomen. All incisions were made to a depth that included skin, fat, muscle, and facia through the peritoneum. The peritoneum was surgically closed using appropriate suture. This method of application mimics the intended clinical usage. The animals were euthanized post-surgery at pre-defined time points based on their cohort designation (1, 3, 6, and 9 months, respectively) for pathological and histopathological examination (3 animals/sex/time point/group) (Tables 1 and 2).

Table 2.

Study Design.

Group	Treatment	Scheduled Termination Event
		1 Month		3 Months		6 Months		9 months
		M	F	M	F	M	F	M	F
1	Two Incisions Sham (Surgery Only)	3	3	3	3	3	3	3	3
2	Two Incisions; Placebo	3	3	3	3	3	3	3	3
3	One Incision; D-PLEX	3	3	3	3	3	3	3	3
4	Two Incisions; D-PLEX	3	3	3	3	3	3	3	3

M: males; F: females.

Clinical Observations

In-cage observations were made at least twice daily, and detailed clinical observations were made weekly, including detailed evaluation of the incision site and dental assessment for teeth discoloration. Body weight measurements were performed at least weekly and food consumption was measured daily. Animals were tested for developmental landmarks (neurobehavioral testing) on Days 28 ± 1, 87 ± 3, 175 ± 4, and 265 ± 5 days. Ophthalmic examination was conducted once within four days of each respective scheduled termination.

Clinical Pathology and Toxicokinetics

Blood samples for clinical pathology (hematology, serum chemistry, and coagulation) were collected on Day 1 (prior to dose) then once within four days of each respective scheduled termination. Urine samples were collected once during acclimation then once within four days of each respective scheduled termination. Toxicokinetics samples were collected on Days 1 (Pre-dose, .5, 1, 2, 4, 10, 12, and 16 hours), 2 (24 ± 1 hours), 3 (48 ± 2 hours), 4 (72 ± 3 hours), 5 (96 ± 4 hours), 8, 15, 22, and 29.

Terminal Procedures

A complete gross necropsy was conducted on fasted animals and the following tissues were collected, preserved, and evaluated macroscopically and microscopically: aorta, bone marrow (femur and sternum), bone (femur and sternum), brain, cervix, incision site, epididymis, esophagus, eyes, and gallbladder. GALT (Gut-associated lymphoid tissue), adrenal gland, lacrimal gland, mammary gland, pituitary gland, prostate, mandibular salivary gland, thyroid gland with parathyroid, heart, kidneys, cecum, colon, rectum, larynx, liver, lung/bronchus, mandibular and mesenteric lymph nodes, quadriceps femoris, optic and sciatic nerves, ovaries/oviducts, pancreas, seminal vesicles, abdominal skin, duodenum, ileum, jejunum, cervical, lumbar and thoracic spinal cord, spleen, stomach, testes, thymus, tongue, trachea, urinary bladder, uterus, vagina, and vas deferens.

Sexual Maturity Assessment

The sexual maturity assessment for males and females was based on morphologic evaluation. For males, this evaluation focused on spermatogenesis in the testes along with the morphology of the epididymides and accessory sex glands (seminal vesicles, prostate gland). For females, the assessment focused on the presence/absence of corpora lutea in the ovaries along with any evidence of repeated cycling in reproductive tissues. Animals were assigned to sexual maturity categories of immature, peripubertal, or mature based on the guidance published by Vidal et al.¹⁶

Statistical Analysis

For statistical analysis, Bartlett’s test for homogeneity was performed with a significance level of .05. If the data was homogeneous (Bartlett’s test result P ≥ .05), a parametric analysis of variance (ANOVA) was performed. If the ANOVA returned “not significantly different” (F-test P ≥ .05), the analysis was stopped. If the ANOVA returned “significantly different” (F-test P < .05), Dunnett’s test was performed to compare dose groups values to those of the sham (control) group. Comparison results with P < .05 were considered significant.

If the data was not homogeneous (Bartlett’s test result P < .05), a non-parametric analysis of variance was performed (Kruskal-Wallis). If the Kruskal-Wallis test returned “statistically different” (P < .05), the Dunn Rank Sum test was performed to compare dose groups values to those of the sham (control) group. If the Kruskal-Wallis test returned “not significantly different” (P ≥ .05), the analysis was stopped. Comparison results with P < .05 were considered significant.

Results

Mortality

There were a total of five unscheduled euthanasia/deaths—two in the sham control group (Group 1), two in the placebo control group (Group 2) and one in the D-PLEX high dose group (Group 4), between Days 5 and 41 following surgery. Mortality events were considered unrelated to the administration of D-PLEX, as four of the five animals were in the control groups, and based on the macroscopic and/or microscopic findings observed in these animals. The one D-PLEX high dose treated animal from Group 4 (284 mg/kg D-PLEX [3.1 mg/kg doxycycline]) was a female swine on Day 4 following surgery. There were no clinical observations noted prior to the animal’s death or macroscopic findings observed and the histopathological evaluation of systemic tissues did not reveal a cause of death for this animal. There was no evidence to suggest a relationship to D-PLEX administration. Microscopic findings of systemic tissues were limited to mild pulmonary hemorrhage and diffuse, mild congestion of the mandibular lymph nodes; these were agonal changes. Morphologic changes at the dosing surgical sites were characterized by neutrophil infiltrates (acute inflammation), diffuse edema, fibrin exudation and hemorrhage with necrotic skeletal muscle in all test groups, as would be expected at this early time point in this incisional surgical model.

Clinical Observations, Clinical Pathology and Body and Organ Weights

There were no D-PLEX placebo-or D-PLEX-related effects on clinical observations, body weight/body weight changes, food consumption, teeth coloration assessment, neurobehavioral and ophthalmic evaluations, hematology, coagulation, serum chemistry, and urinalysis parameters, or organ weights, throughout the time course of the study.

Toxicokinetics

After a single administration of 71 mg/kg (single incision) or 284 mg/kg (142 mg/kg x 2 incisions) dose of D-PLEX, the mean doxycycline plasma concentrations increased gradually from .5 to 2 hours in D-PLEX low dose group (Group 3) and from .5 to 4 hours in D-PLEX high dose group (Group 4), then decreased slowly in both groups. C_max was 112 and 321 ng/mL in the low and high dose D-PLEX groups, respectively (Groups 3 and 4). The Median T_max was 2 hours in both D-PLEX-treated groups (Groups 3 and 4). Mean doxycycline t_1/2 ranged from 27.6 hours in D-PLEX low dose group (Group 3) to 34.4 hours in D-PLEX high dose group (Group 4). Comparison of dose-normalized doxycycline C_max, AUC_last, and AUC_inf indicated dose proportional increases in concentrations with increasing dose (Table 3). Although observed data were available from only 2 dose levels (ie, from Groups 3 and 4), evaluation of linear regression of doxycycline TK parameters vs dose indicated that doxycycline exhibited linear TK characteristics following single dose of local administration of D-PLEX. No differences (determined as >2-fold differences) were observed in female to male ratios for C_max, AUC_last, and AUC_inf in the animals treated by the low or the high dose of D-PLEX (Groups 3 and 4).

Table 3.

Mean (SD) Doxycycline TK Parameters Following Surgical Incision Administration of D-PLEX in Combined Sex Animals.

Group	Dose (mg/kg)	C_max (ng/mL)	T_max (hr)	AUC_last (hr*ng/mL)	AUC_inf (hr*ng/mL)	T_1/2 (hr)	C_max/Dose [(ng/mL)/(mg/kg)]	AUC_last/Dose [(hr*ng/mL)/(mg/kg)]	AUC_inf/Dose [(hr*ng/mL)/(mg/kg)]
3	.77	112 (80.1)	2	1870 (982)	1930 (954)	27.6 (8.34)	146 (104)	2430 (1280)	2500 (1240)
4	3.1	321 (189)	2	8920 (6260)	9230 (6250)	34.4 (10.2)	104 (61.0)	2880 (2020)	2980 (2020)

Macroscopic Observations

There were no macroscopic observations related to the placebo control or test article in any of the tissues evaluated at the 1-, 3-, 6-, or 9-month time points.

Microscopic Observations

1-Month Time Point

The morphologic appearances of the dosing sites in the Sham Control (Group 1), Placebo Control group (Group 2), and D-PLEX groups (Groups 3 and 4) were comparable. They were characterized by the presence of fibrosis and neovascularization (granulation tissue) of similar intensity (usually mild-to-moderate) in the region of the surgically created incision (Figure 1(A)-(D)). Similarly, the degree and incidence of inflammation was comparable across all groups. Specifically, in the Placebo control group (Group 2) and both D-PLEX groups (Groups 3 and 4), there were infiltrations of minimal-to-mild numbers of lymphocytes, macrophages, and multinucleated giant cells within the surgical tissue planes. This foreign body-type response was composed of phagocytic macrophages and giant cells in association with minimal-to-mild (Grade 1 to Grade 2) amounts of material (sometimes calcified), consistent with residual placebo (PLEX excipients as a biodegradable drug delivery platform) or D-PLEX (PLEX excipients plus doxycycline). For the D-PLEX groups (Groups 3 and 4), there were no apparent dose-related differences in the intensity of the inflammatory response. Other findings noted across groups included the presence of microgranulomas associated with surgical foreign material (gauze/cotton and/or hair-shaft fragments) or suture material-related inflammation.

Figure 1.

(A) Low magnification image of the left dosing site from a female swine treated with D-PLEX placebo (Group 2) at 1 month, demonstrating a grade 2 fibrosis and grade 3 neovascularization at the incision site (circles). Arrows indicate grade 2 PLEX residual material. High magnification image of the boxed area is provided in Figure 1(B). (B) High magnification image of the boxed area of Figure 1(A), demonstrating the residual PLEX material, some of it appears as calcified material (arrows), associated with macrophages and multinucleated giant cells (arrowheads). (C) Low magnification image of the right dosing site from a female swine treated with D-PLEX 3.1 mg/kg (Group 4) at 1 month, demonstrating a grade 2 fibrosis and grade 3 neovascularization (circles) at incision site. Asterisks indicate suture material. The boxed area and arrow indicate grade 1 residual D-PLEX material. High magnification image of the boxed area is provided in Figure 1(D). (D) High magnification image of the boxed area of Figure 1(C), demonstrating the residual D-PLEX material, some of it appears as calcified material (arrows), associated with macrophages and multinucleated giant cells (arrowheads). (E) Low magnification image of the left dosing site from a male swine treated with D-PLEX placebo (Group 2) at 9 months, demonstrating the healed incision site with well-organized fibrosis (circles). High magnification image of the boxed area is provided in Figure 1(F). (F) High magnification image of the boxed area of Figure 1(E), demonstrating birefringent microparticulate consistent with minute amount of inert residual PLEX with associated macrophages (arrow). Arrowheads indicate minimal focus of adjacent infiltrating lymphocytes. (G) Low magnification image of the right dosing site from a male swine treated with D-PLEX 3.1 mg/kg (Group 4) at 9 months, demonstrating the healed incision site with well-organized fibrosis (between thick lines). High magnification image of the boxed area is provided in Figure 1(H). (H) High magnification image of the boxed area of Figure 1(G), demonstrating residual suture material (asterisk) with associated inflammatory cell infiltrates surrounded by fibrosis.

3-Month Time Point

The dosing sites across all groups continued to have a comparable microscopic appearance with the presence of more organized, healing collagen matrix (fibrosis) with slightly reduced neovascularization as the wound sites continued to mature. Inflammatory cell infiltration (lymphocytes, macrophages, and/or giant cells) decreased in intensity in all groups when compared to the 1-month time point (minimal severity degree). In the D-PLEX placebo and D-PLEX groups (Group 2 and Groups 3-4, respectively), no residual excipient (PLEX) was present, consistent with complete biodegradation of the biomaterial. Only trivial amounts (sometimes calcified) were present as trace quantities in association with infrequent phagocytic macrophages and/or giant cells. The residual amounts of these microparticulates were observed in quantities comparable to surgical foreign microparticulates or other poorly characterized iatrogenic microparticulates (i.e., gauze/cotton fragments or suture fragments) typically associated within surgical sites or wound sites that completely heal in pre-clinical surgical studies in laboratory swine. Additionally, there were no deleterious tissue alterations at the dosing sites in association with the trace microparticulates in all groups.

6-Month and 9-Month Time Points

The dosing/wound sites continued to heal without complication for all treatment groups and were regarded to be completely healed. The degree of extracellular collagen matrix was stable in quantity but increased in quality as collagen was more organized and the connective tissue more clearly bridged the incision line across bundles of skeletal muscle of the abdominal wall. Inflammation was of decreased incidence at the 6-month time point and was essentially negligible across all groups by the 9-month time point. By the 6-month time point only trace microparticulates were observed. By the 9-month time point, evidence of these trace microparticulates was notably reduced in all groups, consistent with continued biodegradation (Figure 1(E)-(H)).

There were no differences in microscopic observations between the placebo- or D-PLEX-treated groups and the sham control group in any of the tested tissues.

Bone Growth and Skeletal Maturation Assessment

There were no aberrations in skeletal maturation in any of the test groups at all time points, and no statistically significant differences in femur length measurements were found between the groups (Table 4). As compared to the Sham Control group (Group 1), the distal femurs of D-PLEX placebo-treated group (Group 2) and D-PLEX-treated groups (Groups 3 and 4) were of similar appearance in terms of articular surface morphology, endochondral ossification of the physis, and tubulation of the distal metaphysis. The growth plates were still open in all bone specimens at the 9-month time point and the width of the physis was reduced, as expected, compared to the earlier time points.

Table 4.

Mean Group Femur Length Measurements.

Cohort	Dose Level (mg/kg)	Males (mm)	Females (mm)
1-Month	0 (sham)	94.00	97.36
	0 (placebo)	95.10	93.98
	∼71 (one incision)	95.67	91.84
	∼274 (two incisions)	96.33	96.99
3-Month	0 (sham)	81.02	78.08
	0 (placebo)	80.34	76.36
	∼71 (one incision)	77.41	77.51
	∼274 (two incisions)	76.76	77.27
6-Month	0 (sham)	78.09	^a
	0 (placebo)	85.32	^a
	∼71 (one incision)	83.55	^a
	∼274 (two incisions)	86.41	^a
9-Month	0 (sham)	89.91	87.01
	0 (placebo)	87.54	86.36
	∼71 (one incision)	90.77	91.09
	∼274 (two incisions)	88.92	88.62 (n = 1)

^aMeasurement/recording error occurred.

Sexual Maturity Assessment

All males and females were immature at the 1-month time point (Table 5). By 3 months, most males and females were classified as peripubertal. At 6 months, most males were classified as mature, and females were classified as a combination of immature and mature. By the 9-month time point, most males and females were classified as mature. There were no patterns or trends in these classifications across groups to suggest that sexual maturation (as determined by tissue morphology) was affected in all treated groups (Groups 2-4) when compared to the Sham Control group (Group 1).

Table 5.

Sexual Maturity Assessment.

	Group 1 (Sham Control)		Group 2 (D-PLEX Placebo)		Group 3 (D-PLEX .77 mg/kg)		Group 4 (D-PLEX 3.1 mg/kg)
	1 month
	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)
Immature	3	3	3	3	3	3	3	3
Peripubertal	0	0	0	0	0	0	0	0
Maturity	0	0	0	0	0	0	0	0
	3 months
	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 2)
Immature	0	0	0	0	0	0	0	0
Peripubertal	3	3	3	3	2	3	3	2
Maturity	0	0	0	0	1	0	0	0
	6 months
	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 2)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)
Immature	0	2	0	1	0	2	0	2
Peripubertal	2	1	0	0	1	0	0	0
Maturity	1	0	3	1	2	1	3	1
	9 months
	Male (n = 2)	Female (n = 2)	Male (n = 2	Female (n = 3)	Male (n = 3)	Female (n = 3)	Male (n = 3)	Female (n = 3)
Immature	0	2	0	0	0	0	0	2
Peripubertal	0	0	0	0	0	0	0	0
Maturity	2	0	2	3	3	3	3	1

Discussion

Here we present the results of a GLP-compliant 9-months follow-up safety and TK study of D-PLEX in an abdominal surgical incision model in juvenile miniature swine. The animals were exposed to a single application of D-PLEX into abdominal surgical incision sites of juvenile Yucatan miniature swine. There were no test item-related effects in all the parameters evaluated in this study. Administration of D-PLEX placebo (PLEX platform without doxycycline) or D-PLEX in both tested doses was not associated with any local toxicity at the incision sites or with any systemic effects including sexual or skeletal maturation, suggesting good safety profile for both D-PLEX formulations and for the PLEX platform.

The TK parameters demonstrated dose proportional increases in doxycycline plasma concentrations with increased local administration dose. Mean C_max values were 112 and 321 ng/mL (in the low and high D-PLEX doses, respectively) while reported systemic administration of doxycycline in swine resulted in a mean C_max value of ∼1 μg/mL.¹⁷ This further demonstrates the low systemic exposure of doxycycline and the safety of D-PLEX in juvenile animals.

We have also evaluated the safety and the incision sites healing in two previous preclinical studies. In one study, D-PLEX was evaluated in adult New Zealand White rabbits after its administration into a sternal surgical defect and on the ventral side of the sternum.⁷ The rabbits were followed for 15 months, and no safety issues were found with the tested material. As expected, D-PLEX gradually degraded until it was fully resorbed by 9 months. Sternal bone strength was not affected by D-PLEX.

In the second study, the safety of D-PLEX in adult Yucatan miniature swine was tested using the same type of incision as in the present study.⁸ Therefore, the current study allows us to compare the wound healing process in between adults and juvenile swine of the same strain as the previous study. In the previous abdominal model study, the swine were 4- to 5-month-old at study initiation (compared to 1-month-old at the current study). As in the current study, there was no evidence for systemic toxicity or other safety concerns in adult swine, and all D-PLEX material was fully absorbed by 6 months whereas most of the material was absorbed during the first 3 months.⁸ In the current study, peritoneal surfaces in all groups were fully healed and there were no notable increases in abdominal adhesions to the incision site for D-PLEX-treated sites compared to the sham control sites. However, in juvenile animals, D-PLEX was fully resolved at the 3-month time point, which is quicker than the 6-month absorption rate observed in the older swine.⁸ The difference in the absorption rate can be explained by an age-related delay in wound healing and less robust constructive remodeling in adult animals.^18,19 Another possible explanation can be related to the notable faster drug release in juvenile vs adult animals as reflected in our studies by decreased T_max and t_1/2 in both tested doses (in mg/kg) supporting the accelerated metabolism in juveniles.⁸ However, mean C_max and AUC values were dose related (in mg/kg) and similar between juvenile and adult swine for both tested doses suggesting similar overall exposure but faster kinetics in the juvenile swine compared with the adult swine.

The similar absorption rate in the placebo group can further support the safety of the formulation, as well as the prolonged exposure to doxycycline also in juvenile swine. This information is encouraging for the future development of additional PLEX-based products to the pediatric population.

During the histopathological evaluation, we have noticed the presence of microgranulomas associated with surgical foreign material (gauze/cotton and/or hair-shaft fragments) or suture material-related inflammation (see, for example, Figure 1(C)). Such observations are normal findings and are a result of the surgical procedure or the routine wound care.^7,20,21 It is however important to correctly interpret these findings, since biomaterials such as the ones used in the current study can also elicit a foreign-body reaction.

In summary, this study, along with the previous in vivo preclinical studies in adult rabbits and adult swine, demonstrates the safety of D-PLEX in abdominal and sternal surgical site models and provides evidence to support further testing of D-PLEX in the pediatric population. In addition, since it provides excellent documentation of the healing process of abdominal incision sites in juvenile minipigs, it can be used as a reference for future preclinical studies aiming to evaluate the safety of different PLEX-based treatments for the pediatric population.

Footnotes

Acknowledgments

The authors thank Tzvia Selzer from PolyPid Ltd for critical review of the manuscript.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.D., S.N., S.R., and N.E. are all current or former employees of PolyPid, Ltd Or PolyPid, Inc. and own stock/stock options. A.N. is a consultant for PolyPid.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by PolyPid Ltd, Petah Tikva, Israel.

ORCID iD

Yuval Ramot

Appendix

References

Ban

Minei

Laronga

et al. American college of surgeons and surgical infection society: surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017;224:59-74.

Klifto

Rydz

Biswas

Hultman

Erdmann

Phillips

. Evidence-based medicine: systemic perioperative antibiotic prophylaxis for prevention of surgical-site infections in plastic and reconstructive surgery. Plast Reconstr Surg. 2023;May 2. DOI: 10.1097/PRS.0000000000010608. Online ahead of print

Hughes

CML

Jeffers

Sethuraman

Klum

Tan

. The detection and prediction of surgical site infections using multi-modal sensors and machine learning: results in an animal model. Front Med Technol. 2023;5:1111859.

Shepard

Ward

Milstone

, et al. Financial impact of surgical site infections on hospitals. JAMA Surgery. 2013;148:907-914.

Zimlichman

Henderson

Tamir

, et al. Health care-associated infections. JAMA Intern Med. 2013;173:2039.

Yamamoto

Yoshitomi

Oshimo

, et al. Ability of minimally invasive surgery to decrease incisional surgical site infection occurrence in patients with colorectal cancer and other gastroenterological malignancies. Frontiers in Surgery. 2023;10:1150460.

Ramot

Nedvetzki

Rosenfeld

Emanuel

Nyska

. Toxicity and safety study of D-plex100 in a sternal surgical defect in New Zealand white rabbits. Toxicol Pathol. 2019;47:504-514.

Ramot

Nedvetzki

Rosenfeld

Rousselle

Nyska

Emanuel

ND-PLEX

. D-PLEX100 in an abdominal surgery incision model in miniature swine: safety study. Toxicol Pathol. 2020;48:677-685.

Zmora

Stark

Belotserkovsky

, et al. A prospective, randomized assessment of a novel, local antibiotic releasing platform for the prevention of superficial and deep surgical site infections. Tech Coloproctol. 2023;27:209-215.

10.

Sheikh

Malik

Karim

. Antibiotic prophylaxis and surgical site infections; a prospective open label study to clinically evaluate the serum and tissue concentration of single dose prophylactic ceftriaxone in laparoscopic cholecystectomy. Eur J Clin Pharmacol. 2020, Jun 25. DOI: 10.1007/s00228-020-02940-x. Online ahead of print

11.

Takayama

Komatsu

Nakamura

, et al. Association of serum and fat tissue antibiotic concentrations with surgical site infections in lower gastrointestinal surgery. Surgery. 2022;171:1000-1005.

12.

Toma

Suntrup

Stefanescu

London

Mutch

Kharasch

. Pharmacokinetics and tissue penetration of cefoxitin in obesity. Anesth Analg. 2011;113:730-737.

13.

Kachel

Moshkovitz

Sternik

, et al. Local prolonged release of antibiotic for prevention of sternal wound infections postcardiac surgery-A novel technology. J Card Surg. 2020;35:2695-2703.

14.

Eeftinck Schattenkerk

Musters

Nijssen

, et al. The incidence of abdominal surgical site infections after abdominal birth defects surgery in infants: a systematic review with meta-analysis. J Pediatr Surg. 2021;56:1547-1554.

15.

Shah

Christensen

Wagner

Pearce

Sweeney

Tait

. Retrospective evaluation of antimicrobial prophylaxis in prevention of surgical site infection in the pediatric population. Pediatric Anesthesia. 2014;24:994-998.

16.

Vidal

Colman

Bhaskaran

, et al. Scientific and regulatory policy committee best practices: documentation of sexual maturity by microscopic evaluation in nonclinical safety studies. Toxicol Pathol. 2021;49:977-989.

17.

Bousquet

Nouws

Terlouw

de Kleyne

. Pharmacokinetics of doxycycline in pigs following oral administration in feed. Vet Res. 1998;29:475-485.

18.

Sicari

Johnson

Siu

, et al. The effect of source animal age upon the in vivo remodeling characteristics of an extracellular matrix scaffold. Biomaterials. 2012;33:5524-5533.

19.

Yao

Visovatti

Johnson

, et al. Age and growth factors in porcine full-thickness wound healing. Wound Repair Regen. 2001;9:371-377.

20.

Ramot

Amir

Willenz

Nyska

. Foreign-body granulomas within intramyocardial arteries in a transcoronary safety assessment in pigs. Toxicol Pathol. 2008;36:385-387.

21.

Sari

Basterzi

Karabacak

Tasdelen

Demirkan

. The potential of microscopic sterile sponge particles to induce foreign body reaction. Int Wound J. 2006;3:363-368.

Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine

Abstract

Keywords

Introduction

Materials and Methods

Treatment Protocol

Surgical Procedures

Clinical Observations

Clinical Pathology and Toxicokinetics

Terminal Procedures

Sexual Maturity Assessment

Statistical Analysis

Results

Mortality

Clinical Observations, Clinical Pathology and Body and Organ Weights

Toxicokinetics

Macroscopic Observations

Microscopic Observations

1-Month Time Point

3-Month Time Point

6-Month and 9-Month Time Points

Bone Growth and Skeletal Maturation Assessment

Sexual Maturity Assessment

Discussion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

ORCID iD

Appendix

References